Usefulness of DORNASE in COVID-19 on HFNO
Study Details
Study Description
Brief Summary
COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme, registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical characteristic. DNAse alfa inhalations are typically well tolerated and with no major side effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients, that had benefitial effects. There are some trials registered with ClinicalTrials, investigating the usufulness of DNAse alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: 4% saline 4% Saline inhalations twice daily |
Drug: Saline
inhalations twice daily
Other Names:
|
Experimental: Pulmosyme DNAse alpha inhalations twice daily |
Drug: Dornase Alfa
inhalations twice daily
|
Outcome Measures
Primary Outcome Measures
- Intubations [7 days]
Number of intubations necessary
Secondary Outcome Measures
- PaO2/FiO2 [7 days]
Increase in PaO2/FiO2 ratio
- inflamation [7 days]
Reduction of inflamation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Positive SARS-CoV-2 RNA PCR swab
-
inflamatory phase of infection
-
HFNO
Exclusion Criteria:
-
pregnancy
-
previous treatment with DNAse alfa
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University Medical Centre Ljubljana
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DTS_pulmosyme